Contract W58P0522C0013
Maxim Biomedical, Inc · Department Of Defense · February 18, 2022
Maxim Biomedical, Inc was awarded a federal contract by Department Of Defense (Department Of The Army) on February 18, 2022 for $54.64 million of work in in-vitro diagnostic substance manufacturing. Performance is in Chambersburg, PA. It was awarded under full and open competition. The contract has been modified 2 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on June 30, 2022.
Contract details
- PIID
- W58P0522C0013
- Award type
- Definitive Contract
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Not Competed
- NAICS
- 325413 · In-Vitro Diagnostic Substance Manufacturing
- Product / service
- Medical And Surgical Instruments, Equipment, And Supplies
- Place of performance
- Chambersburg, PA
- First action
- February 18, 2022
- Latest action
- June 30, 2022
Description
POP EXTENSION AND CONSIDERATION
Modification timeline
-
June 30, 2022Mod P00002$0
-
May 23, 2022Mod P00001UPDATE TO WAWF CLAUSE$0
-
February 18, 2022Base award8 MILLION OTC COVID-19 TEST KITS$54.64M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Diasorin Inc | Department Of Defense | December 31, 2025 | $518.8K |
| Bloodworks | Department Of Defense | December 31, 2025 | $160.2K |
| Sl Meditech Co. | Department Of Defense | December 31, 2025 | $151.6K |
| Alba Bioscience, Inc. | Department Of Defense | December 31, 2025 | $163.2K |
| Werfen USA Llc | Department Of Defense | December 31, 2025 | $18.1K |
| Immucor Inc | Department Of Defense | December 31, 2025 | $154.2K |
Top contractors in NAICS 325413
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Abbott Rapid Dx North America Llc | 651 | $3.51B |
| 2 | Ihealth Labs Inc. | 4 | $2.13B |
| 3 | Roche Diagnostics Corporation | 5,604 | $959.60M |
| 4 | Siemens Healthcare Diagnostics Inc. | 818 | $641.45M |
| 5 | Cepheid | 3,693 | $639.45M |
| 6 | Remel Inc. | 4,525 | $464.47M |
| 7 | Access Bio, Inc. | 5 | $340.72M |
| 8 | Ortho-Clinical Diagnostics, Inc | 1,964 | $227.77M |
| 9 | Quidel Corp | 96 | $194.78M |
| 10 | Ortho-Clinical Diagnostics Inc | 2,494 | $183.46M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract W58P0522C0013?
Contract W58P0522C0013 is a federal contract awarded to Maxim Biomedical, Inc by Department Of Defense on February 18, 2022 for $54.64 million of work classified under IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING. It has been modified 2 times since the base award.
Who won contract W58P0522C0013?
Maxim Biomedical, Inc won contract W58P0522C0013 from Department Of Defense.
How much is contract W58P0522C0013 worth?
Contract W58P0522C0013 has obligated $54.64 million to date.